Antiplatelet agents battle to a standstillThe glycoprotein IIb/IIIa inhibitor tirofiban (Aggrastat) is “non-inferior” to its more expensive counterpart abciximab (ReoPro) in ST-elevation MI patients undergoing percutaneous coronary intervention. Standard-dose heparin best for procedure-related thrombosesCanadian researchers have suggested previously that prevention of catheter thrombosis sometimes seen with the anticoagulant fondaparinux can be attenuated using standard doses of unfractionated heparin. Nurses get to the heart of lifestyle changes When it comes to making positive changes in lifestyle and medication adherence among patients following an acute coronary syndrome, nurses trump “usual care” performed by physicians. Statins in primary prevention: The debate flares up Canadian dyslipidemia guidelines criticized for accepting results of ‘biased’ study Research Highlights: Drug-eluting stents - duration of dual antiplatelet therapy Percutaneous coronary intervention is a procedure used to treat the stenotic coronary arteries found in coronary heart disease. Exposure to virulent E. coli strain sparks renal, cardiac disease Long-term followup of Walkerton victims reveals lasting impact on health Studies boost case for chest-compression-only CPR Emergency physicians all a-flutter over variation in care for atrial fibrillation Care of recent-onset AF by pharmacological means and cardioversion differs markedly in Canada and internationally Adherence poor in stroke patients Cardioplegia gets less invasive First Previous 82 83 84 85 86 Next Last
